[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemorrhagic-strokes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemorrhagic-strokes":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100569583","phase-1-tenecteplase-tnk-in-the-treatment-of-intracerebral-hemorrhage-ich-100569583",false,"NCT06696131","Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)","TNK in ICH","Inclusion Criteria\n\n* Patient\u002Flegally authorized representative has signed the Informed Consent Form.\n* Ability to comply with the study protocol, in the investigator's judgment.\n* Patients 18 to 80 years of age with an ICH had occurred within 24 hours before admission.\n* Spontaneous supratentorial (basal ganglia, thalamus, lobar) ICH ≥30 mL measured utilizing the ABC\u002F2 method.\n* Subjects with a GCS score of 5-14.\n* NIHSS ≥6.\n* Stability CT scan done at least 6 hours after baseline CT showing clot stability (growth \\\u003C5 mL as measured by ABC\u002F2 method). If the hematoma volume measured on the stability CT scan increases by 5 mL or more, a second stability CT scan will be performed 12 hours later.\n* Sustained systolic blood pressure (SBP) \\\u003C180 mm Hg for six hours recorded closest to the time of drug administration.\n* Symptoms must be present less than 24 hours prior to baseline CT scan.\n* Baseline Rankin score of 0 or 1.\n\nExclusion Criteria\n\n* Presence of infratentorial parenchymal bleeding.\n* Presence of a hemorrhage extending to the midbrain.\n* An unknown time of onset or the symptoms onset more than 24 hours prior to admission.\n* Pregnancy.\n* Inability to obtain written informed consent from subject or legal representative.\n* Sustained SBP \\>180 mm Hg for six hours recorded closest to the time of drug administration.\n* Age \\\u003C18 and \\>80 years.\n* Radiological evidence of arterio-venous malformation, aneurysm, amyloid angiopathy, Moyamoya disease, hemorrhagic conversion of an ischemic stroke, recurrent hemorrhage in the same location within the past 365 year or unstable mass as a source for the ICH.\n* Evidence of coagulopathy (international normalized ratio \\>1.3; platelet count \\\u003C100 ,000 or platelet dysfunction P2Y-12 \\>250) or known clotting disorder.\n* Bilateral fixed, dilated pupils indicating irreversible impaired brain stem function with GCS ≤4.\n* Patients with severe ICH and IVH who require an external ventricular drain (EVD) placement for cerebrospinal fluid (CSF) diversion or separate intraventricular thrombolysis.\n* Inability to maintain INR less than 1.3.\n* Use of anticoagulants prior to symptom onset and subjects requiring long-term anticoagulants (the reversal is permitted if the patient can tolerate the short-term risk of reversal).\n* Use of Dabigatran, Apixaban, and\u002For Rivaroxaban (or a similar medication from the similar medication class) prior to symptom onset.\n* Internal bleeding (GI, renal, respiratory etc).\n* Mechanical heart valve (Bioprosthetic heart valve is permitted).\n* Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis (atrial fibrillation without mitral stenosis is permitted).\n* Allergy or sensitivity to TNKase.\n* Participation in a concurrent clinical trial.\n* Serious illness (advanced stage which can interfere with the outcome).\n* The patient is unstable and would not benefit from a surgical intervention.\n* GCS score of 3-4 and 15 (to ensure patient safety and study feasibility).\n* Historical mRS score of 2-6 (at admission).\n* Symptomatic tract hemorrhage or a tract hemorrhage more than 5 mm.","ALL","18 Years","80 Years",{"count":20,"type":21},5,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The overall purpose of this study is to look at the safety and effectiveness of administering Tenecteplase (TNK) into the brain bleed (hematoma) instead of another clot-dissolving drug known as recombinant tissue plasminogen activator (rtPA), which is the current standard practice. Clot dissolving (Fibrinolytic) drugs work to break down blood clots and have been found to improve health outcomes when applied directly into the hematoma within the brain. Patients who take part in this study will undergo the same surgical procedure that would normally be performed to treat them, but with the exception of TNK not rtPA.",[27,28,29],"Intracerebral Hemorrhage","Intracranial Hemorrhages","Hemorrhagic Strokes","NOT_YET_RECRUITING","2026-04-24",{"date":33,"type":34},"2026-04-30","ACTUAL",{"date":36,"type":21},"2026-09-15",{"date":38,"type":21},"2028-12-31",{"name":40,"class":41},"Gaurav Gupta, MD","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100611166","phase-2-minocycline-in-stroke-study-at-maimonides-100611166","NCT07237048","Minocycline in Stroke Study at Maimonides","Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial","\\* Inclusion criteria\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age \\>\u002F=18\n2. NIHSS 5-20 \\*National Institutes of Health Stroke Scale\\*\n3. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO \\*(World Health Organization) \\* guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed\n4. The onset of neurological symptoms less than 24 hours\n\n   * Exclusion criteria\n\nAn individual who meets any of the following criteria is excluded from participation in this study:\n\n1. Clinically stroke is not suspected\n2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline\n3. Pregnancy or suspected pregnancy or breastfeeding\n4. Previous history of intolerance to Minocycline\n5. Acute or chronic renal failure (stage III with GFR \\*(Glomerular Filtration Rate) \\* or Creatinine threshold)\n6. Any patients with contraindications to undergo CT (Computed Tomography) \u002F MRI (Magnetic Resonance Imaging)\n7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission\n8. Pre-existing infectious disease requiring antibiotics\n9. Inability to tolerate enteral medications\u002Ffeeds\n10. Patient\u002F family refusal",{"count":50,"type":21},1164,[52,53],"PHASE2","PHASE3","The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older.\n\nThe main questions it aims to answer are:\n\n1. Does Minocycline improve \\*National Institutes of Health Stroke Scale\\* (NIHSS) scores at hospital discharge and 90 days post-stroke?\n2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\\*Modified Rankin Scale\\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care?\n\nResearchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality.\n\nParticipants will:\n\n1. Be randomly assigned by block to receive either:\n\n   Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only\n2. Undergo neurological assessments using NIHSS \\*National Institutes of Health Stroke Scale\\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke\n3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses\n\nNIHSS: \\*National Institutes of Health Stroke Scale\\*, which is stroke severity scale,\n\nmRS: \\*Modified Rankin Scale\\*, which is stroke disability scale",[56,57,29,58,59,60,61],"Stroke","Ischemia Stroke","Mortality","Morbidity","Cerebrovascular Accident (Stroke)","Intracerebral Haemorrhage (ICH)",[63,64,65,66,67,68,69,70,71,72,59,58,73,74,75,76],"Minocycline","Acute Stroke","Neuroprotection","Ischemic Stroke","Hemorrhagic Stroke","NIH Stroke Scale","Modified Rankin Scale (mRS)","Stroke Recovery","Stroke Treatment","Stroke Outcomes","Intravenous Thrombolysis","Mechanical Thrombectomy","Hemorrhagic Transformation","Oral antibiotic","RECRUITING","2026-03-18",{"date":80,"type":34},"2026-03-19",{"date":82,"type":34},"2026-02-02",{"date":84,"type":21},"2028-12",{"name":86,"class":41},"Joyce Chen",1]